Terry Smith Blasts Novo, Coloplast in Danish Life Science Rebuke
Summary by Bloomberg
2 Articles
2 Articles
All
Left
1
Center
Right
Terry Smith: H1 2025 Performance – Winners, Losers, and What’s Next | The Acquirer's Multiple®
Terry Smith’s mid-year letter for the Fundsmith Equity Fund opens with a direct assessment of performance. In a period marked by underperformance relative to the MSCI World Index, Smith offers investors a characteristically clear update: “Our Fund fell 1.9% in the first six months of the year,” while “the MSCI World Index (£ net)” eked out a 0.1% gain. Though he acknowledges the underperformance, Smith is quick to frame it as driven by a handful…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium